Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Biotech M&A expected to be a 'different animal' in 2022
View:
Post by Noteable on Aug 10, 2022 1:02pm

Biotech M&A expected to be a 'different animal' in 2022

Biopharmas have USD$ 1.7 Trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions. 

https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t
Comment by Noteable on Aug 10, 2022 1:06pm
" Increased scrutiny from the US Federal Trade Commission (FTC) around larger deals could mean that 2022 will be a year of bolt-on transactions in the $5 to $15 billion range as pharma companies take multiple shots on goal in order to make up for revenues lost to generic competition in the remainder of the decade. However, don’t rule out the potential for larger deals — consolidation is good ...more  
Comment by Lesalpes29 on Aug 10, 2022 1:06pm
  Again... they are hunting around us! 
Comment by Noteable on Aug 10, 2022 1:09pm
One of the purists wrote: "Again... they are hunting around us! "  Says who ??!!!
Comment by Lesalpes29 on Aug 10, 2022 1:30pm
I'm not a purist nor a dreamer! To see old posts talking about deals in billions and us at 70 millions doesn't make any sense. Find us relevant information!
Comment by Noteable on Aug 10, 2022 1:34pm
Says who ??!!
Comment by Lesalpes29 on Aug 10, 2022 1:37pm
Broken record! S N L probably! Anyway will stop to tead your continual repostings!
Comment by Noteable on Aug 10, 2022 1:45pm
Well I am perfectly fine with you deciding to stop reading and then posting empty responses to my posts. 
Comment by Lesalpes29 on Aug 10, 2022 1:51pm
Just one question for you... why are you shooting the same information week after week? It's probably empty too! Or worst getting People frustrated!
Comment by Noteable on Aug 10, 2022 1:59pm
You said you would stop responding to my posts. What's you're problem? Can't keep your word? More of your empty promises? Frustrated by your bad decisions to bet against the rising trend in Big Pharma expected flurry of M&A activities going into the latter H2 '22 ?
Comment by Noteable on Aug 10, 2022 2:00pm
Should read : What's your problem?
Comment by Lesalpes29 on Aug 10, 2022 2:04pm
It was my last post for you only! Keep your good work my favorite stop clock!
Comment by Noteable on Aug 13, 2022 8:31pm
This seems to have been lost to some so I will repost - Biopharmas have USD$ 1.7 Trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.  https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities